Australia’s Sigma drops out of talks to buy UK’s Boots
Australian pharmaceutical group Sigma Healthcare has withdrawn from talks to acquire the UK retail chain Boots. Sigma stated that a deal, estimated at $10 billion (£7 billion), would not align with its strategic and capital investment objectives.

Briefing Summary
AI-generatedAustralian pharmaceutical group Sigma Healthcare has withdrawn from talks to acquire the UK retail chain Boots. Sigma stated that a deal, estimated at $10 billion (£7 billion), would not align with its strategic and capital investment objectives. The company plans to focus on its established growth strategy within the Australian market. Sigma's withdrawal prolongs uncertainty for the 177-year-old British company, which has been on the market since 2022. Other interested parties, including the Canadian branch of the Weston family, remain. Boots, which has 1,800 UK stores and reported increased revenues and profits, was last acquired by Walgreens in 2014.
Article analysis
Model · rule-basedKey claims
5 extractedSigma finalized a merger with Chemist Warehouse to create a A$30bn group, with Sigma shares increasing more than threefold since the deal was announced.
Boots reported revenues rose 3.2% to £7.5bn and pre-tax profit up 25% to £337m in the year to August 2025.
Sigma stated a deal to buy Boots would not meet its strategic and capital investment objectives.
Sigma Healthcare has dropped its pursuit of the UK retail chain Boots, abandoning a takeover estimated to be worth $10bn (£7bn).
Shares in Sigma jumped 6% on Monday, with investors appearing to breathe a sigh of relief.